Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | March 12, 2017 | March 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date March 12, 2017 · Filed March 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 169,614 |
Reported balance
After 2018-03-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-12 · Exercise / conversion · Acquired 6,586 · Balance 169,614 F1: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 121,114 shares of common stock held by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 164,935 |
Reported balance
After 2018-03-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-03-12 · Tax withholding · Disposed 4,679 · Balance 164,935 F2: Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934. F3: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 116,435 shares of common stock held by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 142,685 |
Reported balance
After 2018-03-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2018-03-14 · Sale · Disposed 22,250 · Balance 142,685 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F5: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 94,185 shares of common stock held by the Reporting Person. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2018-05-22 | Direct | 0 |
Reported balance
After 2018-03-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-12 · Exercise / conversion · Disposed 6,586 · Balance 0 F6: Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 121,114 shares of common stock held by the Reporting Person.
F2: Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934.
F3: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 116,435 shares of common stock held by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F5: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 94,185 shares of common stock held by the Reporting Person.
F6: Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2018 Filed Mar 16, 2018 01:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 22,250 | $4.58 | $101,905.00 |
DisclosureSEC source: 0001209191-18-020046 · doc4.xml · nonDerivative · entry 3 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,685 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F5 · balance_after: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 94,185 shares of common stock held by the Reporting Person. Read SEC document |
| March 12, 2018 Filed Mar 16, 2018 01:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 6,586 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001209191-18-020046 · doc4.xml · derivative · entry 4 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 6,586 shares Expires 2018-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended. Read SEC document |
| March 12, 2018 Filed Mar 16, 2018 01:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 4,679 | $4.80 | $22,459.20 |
DisclosureSEC source: 0001209191-18-020046 · doc4.xml · nonDerivative · entry 2 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,935 F2 · shares: Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934. F3 · balance_after: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 116,435 shares of common stock held by the Reporting Person. Read SEC document |
| March 12, 2018 Filed Mar 16, 2018 01:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 6,586 | $3.41 | $22,458.26 |
DisclosureSEC source: 0001209191-18-020046 · doc4.xml · nonDerivative · entry 1 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 121,114 shares of common stock held by the Reporting Person. Read SEC document |
| March 07, 2018 Filed Mar 12, 2018 21:26 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 35,054 | $4.61 | $161,598.94 |
DisclosureSEC source: 0001209191-18-018913 · doc4.xml · nonDerivative · entry 1 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,028 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 114,528 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 13:47 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 17,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001624 · doc4.xml · nonDerivative · entry 1 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,082 F1 · shares: Represents a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2018. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 149,582 shares of common stock held by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 21,213 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · derivative · entry 9 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 21,213 shares Expires 2022-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 22,545 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · derivative · entry 8 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 22,545 shares Expires 2020-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 23,720 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · derivative · entry 7 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 23,720 shares Expires 2019-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 16,709 | $3.25 | $54,304.25 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · nonDerivative · entry 6 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,882 F2 · shares: Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934. F7 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 138,432 shares of common stock held by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 21,213 | $2.56 | $54,305.28 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · nonDerivative · entry 5 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 155,141 shares of common stock held by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 17,967 | $3.25 | $58,392.75 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · nonDerivative · entry 4 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,378 F2 · shares: Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934. F5 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 133,928 shares of common stock held by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 22,545 | $2.59 | $58,391.55 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · nonDerivative · entry 3 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 151,895 shares of common stock held by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 16,640 | $3.25 | $54,080.00 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · nonDerivative · entry 2 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,800 F2 · shares: Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934. F3 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 129,350 shares of common stock held by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 23,720 | $2.28 | $54,081.60 |
DisclosureSEC source: 0001209191-17-052216 · doc4.xml · nonDerivative · entry 1 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 145,990 shares of common stock held by the Reporting Person. Read SEC document |
| May 25, 2017 Filed May 31, 2017 00:38 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 31,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036300 · doc4.xml · nonDerivative · entry 1 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,720 F1 · shares: Represents a deferred stock award of 31,300 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018. F2 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 16,725 restricted stock units which vest quarterly in equal installments on June 30, 2017, September 30, 2017 and December 31, 2017; and (c) 116,695 shares of common stock held by the Reporting Person. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:58 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 22,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001111 · doc4.xml · nonDerivative · entry 1 UVEGES GEORGE · CIK 0001124927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,420 F1 · shares: Represents a deferred stock award of 22,300 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2017. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 22,300 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 85,820 shares of common stock held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.